Human intestinal organoids provide a scalable and highly predictive model system for studying the effects of novel therapeutics in vitro. Intestinal organoids contain the relevant cell types that constitute the intestinal epithelium and, as such, can be maintained in various states of proliferation or differentiation. These physiologically relevant models reveal the toxicity of compounds that can not be seen in Caco-2 cells, which are frequently used to model the intestine during drug development programs.

In this webinar, Dr. Victoria Conlin and Johnny Aether from STEMCELL Technologies will describe, in detail, what intestinal organoids are, how they mimic the immunocytochemistry and morphology of the human gut epithelium, and how to use organoids for drug screening. They will also discuss the intestinal organoid assays offered by Contract Assay Services (CAS) at STEMCELL Technologies.

Key learning objectives will include:

• Learn about the importance of the intestinal epithelium in early determination of drug toxicity
  
• Discover applications of intestinal organoid cultures in:
  
• Drug discovery, including how organoid-derived intestinal cell cultures can be applied to assess the toxicity of potential therapeutic compounds


• Modeling barrier function


• Explore intestinal organoid assays provided by Contract Assay Services, STEMCELL Technologies' Contract Research Organization (CRO)